XML 36 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities    
Net loss $ (77,424) $ (219,710)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,151 843
Amortization of premiums and discounts on marketable securities 0 (79)
Non-cash lease expense 2,437 1,754
Impairment of long-lived assets 7,579 710
Loss on disposal of property and equipment 273 477
Stock-based compensation expense 6,582 22,524
Non-cash interest expense 0 455
Warrant liabilities revaluation (2,558) (12,746)
Contingent value right liability revaluation 36,900 18,300
Forward contract liabilities revaluation 6,890 149,600
Loss on extinguishment of debt 0 740
Provision (benefit) for deferred taxes 287 (19,000)
Changes in operating assets and liabilities:    
Accounts receivable 4,998 726
Unbilled receivable 2,981 181
Prepaid expenses, deposits and other assets 1,747 (1,265)
Accounts payable (2,927) 2,834
Deferred revenue (5,849) 5,256
Accrued expenses and other liabilities (6,741) (2,761)
Net cash used in operating activities (23,674) (51,161)
Cash flows from investing activities    
Cash assumed in acquisition of Old Cartesian 0 6,561
Proceeds from maturities of marketable securities 0 28,254
Purchases of property and equipment (9,093) (206)
Proceeds from the sale of property and equipment 351 0
Net cash (used in) provided by investing activities (8,742) 34,609
Cash flows from financing activities    
Proceeds from issuance of Series A Preferred Stock, gross in private placement 40,000 20,250
Repayments of principal, final payment fee, and prepayment penalty on debt 0 (27,457)
Net proceeds from issuance of common stock and Series B Preferred Stock in private placement 124,438 0
Equity offering costs (66) 0
Proceeds from exercise of common warrants 2,877 0
Settlement of outstanding equity awards at Merger 0 (6,169)
Proceeds from exercise of stock options 1,179 0
Proceeds from issuance of common stock under Employee Stock Purchase Plan 0 231
Net cash provided by (used in) financing activities 168,428 (13,145)
Effect of exchange rate changes on cash (21) (53)
Net change in cash, cash equivalents, and restricted cash 135,991 (29,750)
Cash, cash equivalents, and restricted cash at beginning of period 78,288 108,038
Cash, cash equivalents, and restricted cash at end of period 214,279 78,288
Supplement cash flow information    
Cash paid for interest 0 1,853
Non-cash investing and financing activities    
Issuance of common stock, license agreement in stock-based compensation expense 0 1,500
Purchase of property and equipment not yet paid 847 128
Equity offering costs in accrued liabilities $ 451 $ 0